The Consensus icMDS is a research project dedicated to providing high-quality patient-reported outcome data in the rapidly evolving treatment landscape in myelodysplastic syndromes (MDS)

Background
Objectives
Project team
Publications

Background

In recent years, important treatment advances have been made for patients with MDS and several new therapies are currently under development. In this changing therapeutic environment, assessing patient reported outcomes, including health related quality of life (HRQoL), has become increasingly important.

HRQoL is now considered a key treatment goal for both lower and higher risk MDS patients, and robust PRO data are essential to support informed treatment decisions and to evaluate the benefit and risk profile of emerging therapies.

Objectives

To develop a common PRO metric, the icMDS-PRO score, to be used consistently across MDS trials and facilitate comparison of study results.

Project Team

Fabio Efficace	Principal Investigator, GIMEMA
Amer Zeidan	Co-Principal Investigator, Yale University, New Haven, US.
Rena Buckstein	Co-Principal Investigator, Sunnybrook Research Institute, Toronto, Canada.
Mikkael Sekeres	University of Miami, Miami, US.
Gregory Abel	Harvard Medical School, Boston, US.
Esther N. Oliva	NHS Trust, London, UK.
Francesca Tartaglia	Project Coordinator, GIMEMA
Daniela Krepper	Project Coordinator, GIMEMA

Contacts

Fabio Efficace: f.efficace@gimema.it
Francesca Tartaglia: f.tartaglia@gimema.it
Daniela Krepper: d.krepper@gimema.it